Patient disposition
| Patient disposition, n (%) . | Cohorts I + III (n = 23) . | Cohort II (n = 2) . | Total (N = 25) . |
|---|---|---|---|
| Patients who ended in cycle 1 | 15 (65.2) | 2 (100.0) | 17 (68.0) |
| Progressive disease | 9 (39.1) | 0 (0.0) | 9 (36.0) |
| Adverse event | 4 (17.4) | 1 (50.0) | 5 (20.0) |
| Physician decision | 2 (8.7) | 1 (50.0) | 3 (12.0) |
| Patients who ended in cycle 2 | 7 (30.4) | 0 (0.0) | 7 (28.0) |
| End of core study | 6 (26.1) | 0 (0.0) | 6 (24.0) |
| Adverse event | 1 (4.3) | 0 (0.0) | 1 (4.0) |
| Patients who ended in retreatment | 1 (4.3) | 0 (0.0) | 1 (4.0) |
| Patient disposition, n (%) . | Cohorts I + III (n = 23) . | Cohort II (n = 2) . | Total (N = 25) . |
|---|---|---|---|
| Patients who ended in cycle 1 | 15 (65.2) | 2 (100.0) | 17 (68.0) |
| Progressive disease | 9 (39.1) | 0 (0.0) | 9 (36.0) |
| Adverse event | 4 (17.4) | 1 (50.0) | 5 (20.0) |
| Physician decision | 2 (8.7) | 1 (50.0) | 3 (12.0) |
| Patients who ended in cycle 2 | 7 (30.4) | 0 (0.0) | 7 (28.0) |
| End of core study | 6 (26.1) | 0 (0.0) | 6 (24.0) |
| Adverse event | 1 (4.3) | 0 (0.0) | 1 (4.0) |
| Patients who ended in retreatment | 1 (4.3) | 0 (0.0) | 1 (4.0) |